company background image
PTX

Prescient Therapeutics ASX:PTX Stock Report

Last Price

AU$0.13

Market Cap

AU$92.1m

7D

-1.9%

1Y

-36.3%

Updated

28 Jan, 2023

Data

Company Financials

Prescient Therapeutics Limited

ASX:PTX Stock Report

Mkt Cap: AU$92.1m

PTX Stock Overview

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia.

PTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Prescient Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prescient Therapeutics
Historical stock prices
Current Share PriceAU$0.13
52 Week HighAU$0.26
52 Week LowAU$0.12
Beta0.76
1 Month Change-1.92%
3 Month Change-20.31%
1 Year Change-36.25%
3 Year Change136.11%
5 Year Change93.18%
Change since IPO-99.82%

Recent News & Updates

Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Nov 22
Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Jun 19
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Recent updates

Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Nov 22
Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Jun 19
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Feb 27
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Aug 26
We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

May 08
Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Jan 11
Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Shareholder Returns

PTXAU BiotechsAU Market
7D-1.9%-1.4%0.6%
1Y-36.3%11.8%3.5%

Return vs Industry: PTX underperformed the Australian Biotechs industry which returned 11.8% over the past year.

Return vs Market: PTX underperformed the Australian Market which returned 3.5% over the past year.

Price Volatility

Is PTX's price volatile compared to industry and market?
PTX volatility
PTX Average Weekly Movement9.3%
Biotechs Industry Average Movement9.1%
Market Average Movement8.5%
10% most volatile stocks in AU Market15.7%
10% least volatile stocks in AU Market3.5%

Stable Share Price: PTX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PTX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1986n/aSteven Yatomi-Clarkehttps://ptxtherapeutics.com

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR.

Prescient Therapeutics Limited Fundamentals Summary

How do Prescient Therapeutics's earnings and revenue compare to its market cap?
PTX fundamental statistics
Market CapAU$92.13m
Earnings (TTM)-AU$5.12m
Revenue (TTM)AU$1.89m

48.8x

P/S Ratio

-18.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTX income statement (TTM)
RevenueAU$1.89m
Cost of RevenueAU$0
Gross ProfitAU$1.89m
Other ExpensesAU$7.01m
Earnings-AU$5.12m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0071
Gross Margin100.00%
Net Profit Margin-270.85%
Debt/Equity Ratio0%

How did PTX perform over the long term?

See historical performance and comparison